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Mutations affecting protein interactions <p>A method is presented to identify residues that form part of an interaction interface, leading to the prediction that 1,428 OMIM muta- tions are related to an interaction defect.</p>
Abstract
We present a novel method that combines protein structure information with protein interaction
data to identify residues that form part of an interaction interface. Our prediction method can
retrieve interaction hotspots with an accuracy of 60% (at a 20% false positive rate). The method
was applied to all mutations in the Online Mendelian Inheritance in Man (OMIM) database,
predicting 1,428 mutations to be related to an interaction defect. Combining predicted and hand-
curated sets, we discuss how mutations affect protein interactions in general.
Background
Interactomics, the study of physical interactions between bio-
logical molecules, is establishing itself as a complementary
approach to decode biological function. The growing flood of
molecular interaction data has been compared to the develop-
ment of genome sequencing in the past decade [1]. More than
20,000 human protein interactions have been deposited in
protein interaction databases [2] and many more can be
inferred from other model organisms. Despite the fact that
these interactions are assumed to constitute only a fraction of
the full protein interaction network in a human cell [3], the
data can already provide valuable information [4,5].
A wealth of investigations have been undertaken to deepen
our understanding of hereditary diseases. As a result of that,
databases such as the Online Mendelian Inheritance in Man
(OMIM) [6] and UniProt [7] together contain almost 30,000
experimentally verified mutations. Nevertheless, the exact
mechanisms by which mutations alter a protein's function are
in many cases poorly understood. Most of the known disease-
related mutations are non-synonymous single nucleotide pol-
ymorphisms in the coding regions of a gene (nsSNPs) [8],
a l t h o u g h  s t o p  a n d  n o n s e n s e  m u t a t i o n s  p l a y  a  r o l e  i n  a
number of hereditary diseases, too [9]. Recent studies also
stress the importance of changes in splicing and post-transla-
tional modification as causes of disease [10]. It has been sug-
gested that up to 80% of disease-associated nsSNPs
destabilize the protein through steric or electrostatic effects
[8,11]. Ferrer-Costa et al. [12] compared disease-associated
and neutral nsSNPs in 73 proteins and estimated that 10% of
disease-associated nsSNPs may affect the quaternary struc-
ture of the protein, thereby changing protein interactions.
In this study, we focus on those diseases that are caused by
mutations in protein interaction interfaces. In recent years,
some interaction-related diseases, such as Alzheimer's and
Creutzfeldt-Jacob disease, have received much attention
[4,13,14]. These conditions feature an induced aggregation of
proteins, often called amyloidosis. Furthermore, diseases can
also be caused by the disruption of protein binding. A typical
example is Charcot-Marie-Tooth disease, which can be trig-
gered by the loss of interaction between myelin protein zero
monomers that link adjacent membranes of the myelin
sheath [15]. To our knowledge, neither type of interaction-
related mutations has yet been studied in a systematic way.
We describe a method that combines protein structure with
experimental protein interaction data in order to
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computationally identify residues that form part of a binding
interface. We apply this algorithm to mutations from OMIM
and UniProt, identifying 1,428 mutations that are likely to
affect protein interactions. Subsequently, we collected
numerous topical reports of changes in protein interaction
that result in disease. We present a list of 119 interaction-
related mutations causing 65 different diseases that was
derived manually from the scientific literature. On the basis
of these sets we discuss general properties of interaction-
related mutations.
Results and discussion
Prediction algorithm
In order to identify residues in a protein that are involved in
a protein interaction, we devised a method that combines
structural and experimental information. Using the iPfam
[16] database of known interacting domains, we first select
domain regions on all target proteins that have a homologous
structure including interaction partners in the PDB [17] (see
Materials and methods). We then select positions that form
residue-to-residue contacts between distinct polypeptide
chains in these structural templates and record the corre-
sponding positions in the target proteins as potentially inter-
acting residues.
We needed to choose a scoring function that discriminates
between residues that are really involved and crucial for an
interaction and those that are not. For this purpose, we tested
the effect of two different variables on prediction accuracy.
Percent sequence identity with structural template
There is a well known correlation between sequence similar-
ity and structural similarity [18], which also extends to inter-
acting domains [19]. An interaction is more likely to be
conserved and to display similar topology when sequence
similarity is high. Although we find that percentage identity
by itself is not a good predictor of the importance of a residue
for an interaction, it can improve the prediction accuracy
slightly when combined with another threshold (Figure 1).
Conservation of mutated residues
For all identified interaction-related mutations, we calculated
a conservation score (see Materials and methods). This score
reflects the frequency with which an amino acid occurs at a
given position in a protein family, relative to a universal back-
ground distribution. If we look at the frequency of conserva-
tion scores over all wild-type compared to all mutated alleles
(Figure 1), we find that the scores for both wild-type as well as
mutated alleles seem to follow a normal distribution. How-
ever, the latter exhibit markedly smaller average conservation
scores (2.4 versus -2.2; Figure 2). Thus, a residue that is
found in the wild type of a protein will generally be more con-
served than the residue found in the mutated version [20].
We therefore tested whether conservation could be used as an
indicator of the functional importance of a residue, even for
surface exposed residues like the ones under investigation
here.
Prediction accuracy
To estimate the accuracy of our prediction approach, we used
the ASEdb database of alanine scanning energetics experi-
ments in protein binding [21] as a 'gold-standard' test set (see
Materials and methods). In such an alanine scan, residues in
the binding interface of a protein are mutated to alanine by
site-directed mutagenesis [22]. The difference in binding free
energy (ΔΔG) between wild-type (ΔG0) and mutated (ΔGA)
protein describes the contribution of a particular residue at
position i to the total binding free energy:
ΔΔGi = ΔGO - GA,i
We assessed how well our method could predict residues with
a large change in ΔG  upon mutation. Randles et al. [23]
showed that for two model proteins, ΔΔG was correlated with
the severity of disease. They show that even changes <2 kcal/
mol could cause disruption of protein binding. Here, we
defined a residue as correctly identified (true positive) if ΔΔG
> 2.5. This threshold is also used in another recent publica-
tion [24]. Residues below this threshold were considered neu-
tral (false positive). This criterion might in itself cause some
'false-negatives', that is, some residues might be crucial for
the function of the protein despite a measured ΔΔG < 2.5, but
we considered a conservative threshold to be preferable.
Figure 1 shows the receiver operator characteristic (ROC)
curve [25], a plot of the frequency of true positive over the fre-
quency of false positive predictions for a given algorithm.
From left to right, points mark decreasing score thresholds,
until no thresholds are applied any more and both true posi-
tive as well as false positive rates reach 100% in the upper
right corner.
The green and red lines represent the performance of our
algorithm using either percentage sequence identity (green)
or residue conservation (red) to score the predictions. With
both scoring methods, our method retrieves more true posi-
tives than would be expected by chance. The conservation
threshold, however, is far superior in distinguishing true from
false positives. At a false positive rate of ≈20%, we can achieve
a true positive rate of almost 60%. These benchmark results
underline that we are able to identify interaction disruptive
mutations with reasonable confidence. The real accuracy
could be even higher than measured here, considering the
conservative ΔΔG cutoff we chose to define a true positive
residue.
We also tested a combination of the two measures, repre-
sented by a blue line in Figure 1. In this case, the residue con-
servation threshold was combined with a fixed 30% sequence
identity cutoff. The performance improves slightly in the low
false-positive region, yielding a true positive rate of 40% at ahttp://genomebiology.com/2008/9/1/R9 Genome Biology 2008,     Volume 9, Issue 1, Article R9       Schuster-Böckler and Bateman  R9.3
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false positive rate of only 7%. In accordance with this bench-
mark, we decided on a residue conservation threshold of >2
in combination with a 30% sequence identity cutoff for all
subsequent analyses. In order to make our algorithm gener-
ally applicable, two more filters were applied: target proteins
had to have a homologous sequence (BLAST e-value of less
than 10-6) in one of four major repositories for protein inter-
action information (IntAct [26], BioGRID [27], MPact [28] or
HPRD [29]). Subsequently, target proteins were excluded if
no homologous experimental interaction involved both inter-
acting  iPfam domains that were seen in the structural
template.
Application to disease mutations
We applied the prediction algorithm as described above to all
single-residue disease mutations extracted from OMIM and
Conservation difference between wild-type and mutated residues Figure 1
Conservation difference between wild-type and mutated residues. Histogram of conservation of wild-type and mutated residues. Triangles denote the 
residue-conservation frequency of all residues in disease protein regions that map to an iPfam domain. Circles show the conservation of the pathogenic 
alleles (see Materials and methods). Trendlines are added to delineate normal distributions.
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UniProt (see Materials and methods). In the case of disease
mutations, the disruptive nature of a residue mutation is
already known. It is unclear, however, whether an interaction
is in fact taking place and is likely to be mediated by the
domain in question. As described above, mutations were
reported, therefore, only if the disease associated protein has
a close homolog that has been proven experimentally to inter-
act with a protein that contains the same binding partner
domain as seen in the PDB structure the interaction was mod-
eled from (the 'structural template'). For example,
[OMIM:+264900.0011] is a Ser576Arg mutation of the
human coagulation factor IX (PTA). The residue is part of a
trypsin domain and seen to interact with Ecotin. However,
the interaction between PTA and Ecotin is not yet recorded in
ROC curves calculated on a set of alanine scanning experiments Figure 2
ROC curves calculated on a set of alanine scanning experiments. The red line represents the performance of our algorithm when changing only the 
conservation threshold, applying no percentage identity cutoff. The green line shows the performance using only percentage identity as a threshold. The 
blue line reflects performance using conservation as threshold, but applying a 30% sequence identity filter. Confidence intervals where calculated using the 
Statistics::ROC Perl module [59].
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any interaction database; therefore, the mutation cannot be
included in our predictions.
Using these criteria, 1,428 mutations from 264 proteins were
predicted to be interaction-related (Figure 3). The full list is
available in Additional data file 1. In total, we collected 25,322
mutations from OMIM and UniProt. This means that approx-
imately 4% of all mutations could be linked to a protein
interaction.
Amongst these mutations, 454 mapped to a structure that
exhibits an interaction between different proteins (hetero-
interaction), while 1,094 mutations mapped to a structure
with an interaction between two identical proteins (homo-
interaction). This means that 120 mutations are found in
structures of both homo- and hetero-interactions. The large
proportion of homo-interactions can be explained by the
overrepresentation of homo-interactions in the structural
templates set: 70% of all distinct protein pairs in iPfam are
homo-interactions, which is in accordance with recent find-
ings that homo-interactions are more common than hetero-
interactions [30].
Properties of mutations in interaction interfaces
Curated set of interaction-related mutations
In addition to the automatically derived data, we collected 119
mutations in 65 distinct diseases from the scientific literature
for which there is evidence that they change the interactions
of the protein they occur in (see Materials and methods). We
call this the 'curated set' of interaction-related mutations
(Additional data file 2). To our knowledge, it represents the
biggest collection of high confidence interaction-related
mutations to date.
Below, we explore differences between interaction-related
mutations and non-interaction-related mutations. We focus
on the mechanism of the mutation, the mode of inheritance
and residue composition. For most of the 1,428 mutations
from the automatically generated set, no information about
their mode of inheritance or functional mechanism was
instantly available. To allow a comparison with the manually
curated set, we sampled 100 mutations randomly and con-
ducted a manual search of the literature in order to annotate
their properties.
Classification according to function
We suggest a classification that groups mutations according
to their effects into loss of function (LOF) and gain of function
(GOF). Below this broad distinction, the GOF mutations can
be further divided into two groups: pathological aggregation
and aberrant recognition. Similarly, LOF mutations can be
split into one class that disrupts obligate interactions between
protein subunits and another class that interferes with tran-
sient interactions.
From the curated set of interaction-related mutations, 95
mutations result in LOF, 17 in GOF, 4 mutations were
reported to change the interaction preference of the protein
and 3 could not be determined. The class of GOF mutations
that result in protein aggregation contains 12 cases, compris-
ing amyloid diseases like Alzheimer's or Creutzfeldt-Jacob,
but also, for example, sickle cell anemia
[OMIM:+141900.0243]. Five cases result in aberrant recog-
nition; for example, a Gly233Val mutation in glycoprotein Ib
that leads to von Willebrand disease [OMIM:*606672.0003]
by increasing the affinity for von Willebrand factor.
Amongst the LOF mutations, 61 affect transient interactions
and 34 affect obligate interactions. The latter usually render
proteins dysfunctional, for example, in the case of lipoamide
dehydrogenase deficiency caused by impaired dimerization
[31]. LOF mutations in transient interactions cause changes
in localization or transmission of information, exemplified by
a mutation in the BRCA2 gene that predisposes women to
early onset breast cancer: a Tyr42Cys mutation in BRCA2
inhibits the interaction of BRCA2 with replication protein A,
a protein essential for DNA repair, replication and recombi-
nation [32]. Lack of this interaction inhibits the recruitment
Data integration steps for interacting residue prediction Figure 3
Data integration steps for interacting residue prediction. Schematic outline 
of data integration for the prediction of interacting residues. Mutations 
from OMIM and UniProt for which a residue in a homologous structure is 
involved in an interaction are selected. This set is restricted further by 
searching for homologous proteins with known interactions, taken from a 
range of protein interaction databases. We require that the the 
homologous interacting proteins contain the same pair of Pfam domains 
that was observed in the structural template. This results in a set of 1,428 
interaction related mutations.
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of double stranded break repair proteins and eventually leads
to an accumulation of carcinogenic DNA changes.
Mode of inheritance
We investigated the mode of inheritance for all mutations in
the curated set, if information was available in the literature.
All GOF mutations showed dominant inheritance (the two
hemoglobin mutations exhibit incomplete dominance). Out
of 61 LOF mutations for which inheritance information was
available, 24 were autosomal dominant and 37 were reces-
sive. Jimenez-Sanchez et al. [33] studied the mode of inherit-
ance of human disease genes. According to them, mutations
in enzymes are predominantly recessive, while mutations in
receptors, transcription factors and structural proteins are
often dominant. Overall, they find a ratio of 188:335 of dom-
inant to recessive diseases. In our data set, the ratio of domi-
nant to recessive mutations is 41:37 (31:29 in terms of
diseases). This enrichment for dominant mutations is statis-
tically significant, as determined by a two-sided test for equal-
ity of proportions (P-value < 0.014). The increase was seen
across Gene Ontology functional categories, in enzymes as
well as regulators and signaling proteins (data not shown). In
the 100 randomly chosen mutations from the predicted set,
we found a ratio of dominant to recessive mutations of 38:41,
which is very similar to the ratio observed in the curated set
(two-sided test for equality of proportions; P-value > 0.68;
hypothesis of difference in proportions rejected).
In GOF mutations, dominant inheritance is not surprising,
but the high proportion (39%) of dominant LOF mutations is
noteworthy. Dominant inheritance in LOF mutations can be
explained by either haploinsufficency or dominant negative
effects [34]. In yeast, dosage sensitivity of members of protein
complexes has been shown [35]. According to what Papp et al.
call the 'balance hypothesis', stoichiometric imbalances have
negative effects on the function of protein complexes. Domi-
nance would thus be a result simply of a lack of functional
protein subunits.
Dominant negative effects as a result of interallelic comple-
mentation could be an alternative explanation for the
observed enrichment of dominant mutations. For example,
mutations of phenylalanine hydroxylase can lead to phe-
nylketonuria [36] by inhibiting necessary conformational
changes between monomers. In such cases where the protein
function relies on the dynamic interactions between subunits,
a mutation in one of the binding interfaces can actively inhibit
the function of the other bound members of the complex.
Detailed experimental analysis of dominant LOF mutations
could reveal the relative importance of dominant negative
effects compared to haploinsufficency due to stoichiometric
imbalances.
Residue frequency
The residue frequency of the predicted interaction-related
mutations was compared to the frequencies of residues over
all mutation in OMIM and UniProt [37]. We find that the fre-
quency distribution of wild-type residues in interaction-
related mutations is mostly similar to the overall mutational
spectrum, with the exceptions of a significant enrichment in
glycine and, to a lesser extent, a higher frequency of tryp-
tophan and glutamine and a reduced frequency of alanine,
serine and valine (figure in Additional data file 3). The enrich-
ment in glycine can not be readily explained by the composi-
tion of residues on the protein surface or in interaction
interfaces [38,39] but might be due to the disruptive nature of
the residues glycine is most likely to mutate to, namely
arginine, serine and aspartate [37].
Examples of putative interaction-related mutations
In the following section we describe three diseases identified
by our method that appear likely to be related to changes in
protein interaction.
Griscelli syndrome, type 2 [OMIM:#607624]
Griscelli syndrome is a disease that features abnormal skin
and hair pigmentation as well as, in some cases, immunodefi-
ciency due to a lack of gammaglobulin and insufficient lym-
phocyte stimulation. Without bone marrow transplantation,
the disease is usually fatal within the first years of life [40].
The type 2 form of Griscelli syndrome usually maps to the
Rab-27A gene [41]. The RAS domain of Rab-27A shares
46.8% sequence identity with the same domain in Ras-related
protein Rab-3A from Rattus norvegicus. The crystal struc-
ture of Rab-3A interacting with Rabphilin-3A was solved by
Ostermeier and Brunger [42] (PDB:1ZBD; Figure 4). We
found that a Trp73Gly mutation in Rab-27A affects a residue
that is both highly conserved (scores of 5.62 for tryptophan
and -1.84 for glycine) and in the center of the interaction
interface. There is strong evidence that Rab-27A interacts
with Myophillin [43]. For these reasons the Trp73Gly muta-
tion seems likely to affect vesicle transport by reducing affin-
ity of Rab-27A to Myophilin.
Adrenocorticotropin hormone deficiency [OMIM:#201400]
Adrenocorticotropin hormone deficiency is characterized by
a marked decrease of the pituitary hormone adrenocortico-
tropin and other steroids. Its symptoms include, amongst
others, weight loss, anorexia and low blood pressure. Lamolet
et al. [44] identified a Ser128Phe mutation in the T-box tran-
scription factor TBX19 that leads to a dominant LOF pheno-
type [UniProt:O60806, VAR_018387]. The crystal structure
of the homologous T-Box domain from the Xenopus laevis
Brachyury transcription factor [45] (81% sequence identity to
the human TBX19 protein; [PDB:1XBR]) shows that this par-
ticular residue is at the core of the dimerization interface (Fig-
ure 5). The mutation substitutes a small polar with a large
aromatic side-chain. Accordingly, the residue features strong
conservation, while phenylalanine is very rare at this position
(scores of 3.31 and -1.78 for serine and phenylalanine, respec-
tively). Pulichino et al. [46] report that the Ser128Phe muta-
tion shows virtually no DNA binding affinity. We predict thathttp://genomebiology.com/2008/9/1/R9 Genome Biology 2008,     Volume 9, Issue 1, Article R9       Schuster-Böckler and Bateman  R9.7
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this loss of affinity is due to a drop in binding free energy
between monomer and DNA, as compared to the dimer.
Baller-Gerold syndrome [OMIM:#218600]
Baller-Gerold syndrome is a rare congenital disease charac-
terized by distinctive malformations of the skull and facial
area as well as bones of the forearms and hands. The disease
phenotypically overlaps with other disorders like Rothmund-
Thomson syndrome or Saethre-Chotzen syndrome. Seto et al.
[47] reported a case of Baller-Gerold syndrome that also
included features of Saethre-Chotzen syndrome. They identi-
fied an isoleucine to valine substitution at position 156 of the
H-Twist protein as the causative mutation. Experimental
studies using yeast-two-hybrid assays have reported the loss
of H-Twist/E12 dimerization ability as a possible cause of
Saethre-Chotzen syndrome [48].
The basic helix-loop-helix domain of H-Twist shares 45%
sequence identity with the c-Myc transcription factor that was
crystalized by Nair et al. [49] (Figure 6). The structure shows
a dimer of c-Myc and Max bound to DNA. The c-Myc/Max
dimerization is essential for the transcriptional regulation.
The Ile156Val mutation is located at the core of the interac-
tion interface. Although the Ile156Val mutation constitutes a
biochemically similar substitution, reflected by the relatively
high frequency of valine at this position in other helix-loop-
helix proteins (conservation scores 2.76 for isoleucine and
1.23 for valine), the change in volume could slightly change
the interaction propensity. Correspondingly, the Ile156Val
mutation causes a mild form of Baller-Gerold syndrome.
Conclusion
Protein interactions can be the root cause of genetic patholo-
gies, yet their significance for health and disease remain to be
quantified. In this first comprehensive survey, we identified
both known and putative mutations that affect protein
interactions.
We devised an automated method to predict interaction
related residues in proteins. It uses sequence-based homol-
ogy detection to correlate mutations to structures of interact-
ing proteins. When applied to disease causing mutations from
OMIM and UniProt, our algorithm yields a set of 1,428 inter-
action-related mutations. This suggests that approximately
4% of mutations could have an effect on protein interactions.
In comparison to non-interaction related mutations, we
observed an enrichment for dominant or co-dominant
Structure of Rattus norvegicus Ras-related protein Rab-3A [PDB:1ZBD] Figure 4
Structure of Rattus norvegicus Ras-related protein Rab-3A [PDB:1ZBD]. The small G protein Rab3A with bound GTP interacting with the effector domain 
of rabphilin-3A. The residue corresponding to the mutated Trp73 from human RAB27A is highlighted in red, while the two residues in contact with it are 
coloured green.Genome Biology 2008, 9:R9
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mutations in both the curated as well as in the predicted set.
Furthermore, there appear to be subtle differences in the res-
idue composition between interaction related mutations and
disease related mutations in general.
Our curated list of interaction-related diseases underlines
that a wide variety of proteins are susceptible to mutations
that alter protein interaction. The list provides examples to
categorize mutations according to their functional and molec-
ular properties. We found that numerous LOF mutations fea-
ture dominant inheritance, suggesting that stoichiometric
imbalances or failing collaborative mechanisms in protein
complexes frequently result in a dominant phenotype.
Further mutagenesis and protein interaction experiments on
selected examples from our predicted set could shed new light
on the molecular mechanisms behind human genetic dis-
eases. In turn, knowledge of more cases of interaction-related
Structure of X. laevis Brachyury protein [PDB:1XBR] Figure 5
Structure of X. laevis Brachyury protein [PDB:1XBR]. The crystal structure of a T-domain from X. laevis bound to DNA. The residues highlighted in red are 
the mutated Ser128, with green residues representing the contact residues in the partner protein. Blue dashed lines show residue contacts.http://genomebiology.com/2008/9/1/R9 Genome Biology 2008,     Volume 9, Issue 1, Article R9       Schuster-Böckler and Bateman  R9.9
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Structure of the Myc/Max transcription factor complex binding DNA [PDB:1NKP] Figure 6
Structure of the Myc/Max transcription factor complex binding DNA [PDB:1NKP]. Both Myc-c and Max form a basic helix-loop-helix motif. They dimerize 
mainly through their extended helix II regions. The residue that corresponds to Ile156 in H-Twist is Ile550, shown in red. The residue sits at a key position 
of the interface, forming bonds with seven residues in Max, shown in green.Genome Biology 2008, 9:R9
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disease will help to improve the accuracy of prediction
algorithms.
Materials and methods
iPfam
iPfam [16] is a database of interactions between Pfam fami-
lies. It is derived by identifying Pfam families on protein
structures in the PDB. All cases of residue-to-residue proxim-
ity between two family instances of less than 6 Å distance are
collected. iPfam version 20 was employed, containing 3,020
interacting domain pairs composed of 2,147 individual
domains.
Homology detection and alignment
Protein sequences were screened for iPfam families using
hidden Markov models with the pfam_scan.pl script [50]. For
each identified family, matching regions were aligned to
structures in which the respective iPfam family had been
found to interact using hmmalign from the HMMER package
[51]. The percentage sequence identity between all pairs of
aligned regions was calculated using the exact implementa-
tion in the Bio::SimpleAlign BioPerl module.
Conservation
Residue conservation was extracted directly from the Pfam
HMM that matched a sequence region. Using hmmfetch from
the HMMER package, we mapped columns in the alignment
back to states in the profile hidden Markov model. The HMM
Perl library [52] was employed to extract the emission pro-
files and background probabilities. For every mutation, the
log-odds score of the original and the mutated residue were
reported.
Alanine scanning database
The ASEdb database [21] contains 101 experiments extracted
from 74 publications that are available online [53]. There
were 3,010 residue mutations recorded. Mutations leading to
incorrectly folded proteins or premature degradation were
excluded from ASEdb if this information was available in the
source publication. In order to use hidden Markov models to
search for iPfam domains, protein sequences corresponding
to the gene name annotated in ASEdb were retrieved from
UniProt. Only proteins for which all amino acid annotations
in ASEdb matched the sequence were included. For 1,202 res-
idue mutations, a UniProt sequence could be identified.
There were 439 mutations from experiments that involved an
antibody as the binding partner and were subsequently
removed. An additional 81 mutations extracted from recent
publications were added manually.
Disease mutations
Mutation data were collected from UniProt [54] and OMIM
[6]. For UniProt, human sequences with variation informa-
tion were acquired using SRS [55]. The analysis was restricted
to disease-related single residue mutations by regular expres-
sion matching on the variant description line in UniProt
entries. OMIM (omim.txt.Z, genemap) and Entrez gene map-
pings (mim2gene, gene2refseq.gz) were downloaded from the
NCBI FTP server [56] as flat files. Mapping OMIM entries to
a reference sequence is not trivial. To accomplish this, protein
sequences for every gene ID reference in the OMIM entry
were acquired from NCBI and UniProt through SRS. To iden-
tify the correct co-ordinate system that fits an OMIM entry,
combinations of signal peptide and other post-translationally
cleaved regions were considered. If the amino acid annota-
tions in the OMIM entries for a gene matched the residues at
the respective position in the reference sequence, that co-
ordinate system was used.
Compiling the curated set of interaction-related 
mutations
In order to identify known interaction-related mutations, all
OMIM 'Description' fields were searched for keywords such
as 'interaction', 'binding' or 'complex'. For all matching muta-
tions, the available literature was manually evaluated. Subse-
quently, PubMed was searched for the same keywords. Lastly,
cases that were identified by the prediction method were
added if they were found to be known in the literature. If a
mutation was shown to be causative and described to directly
affect a protein interaction, it was added to the list. Mutations
that lead to folding errors were excluded from the data set.
Graphics
Three-dimensional protein images were prepared using VMD
[57] and rendered with PovRay [58].
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The following additional data are available. Additional data
file 1 is an Excel spreadsheet listing all 1,428 predicted inter-
acting mutations and the corresponding structural templates,
homologous interactions and surface accessibilities. Addi-
tional data file 2 is an Excel spreadsheet containing 119 dis-
ease mutations linked to protein interaction defects, derived
from the scientific literature. Additional data file 3 contains a
figure showing the distributions of residue frequencies for all
mutations in OMIM and Uniprot (wild type), the predicted
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described by Chakrabarti et al. [38], the whole of UniProt and
for residues from ASEdb with ΔΔG > 2.
Additional data file 1 All 1,428 predicted interacting mutations and the corresponding  structural templates, homologous interactions and surface  accessibilities All 1,428 predicted interacting mutations and the corresponding  structural templates, homologous interactions and surface  accessibilities. Click here for file Additional data file 2 119 disease mutations linked to protein interaction defects, derived  from the scientific literature 119 disease mutations linked to protein interaction defects, derived  from the scientific literature. Click here for file Additional data file 3 Distributions of residue frequencies for all mutations in OMIM and  Uniprot (wild type), the predicted set (wild type), the curated set,  for interface residues as described by Chakrabarti et al. [38], the  whole of UniProt and for residues from ASEdb with ΔΔG > 2 Error bars for the predicted set were calculated by randomly resa- mpling 1,428 residues from all mutations 1,000 times and calculat- ing the standard deviation. Click here for file
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